News

Bona US releases cleaning pads for hard surfaces

BY Ryan Chavis

AURORA, Colo. — Bona US, a manufacturer and distributor of home care products, announced the launch of Bona Stone, Tile and Laminate Wet Cleaning Pads. The new pads succeed the company's successful Bona Hardwood Floor Wet Cleaning Pad and are formulated for most sealed, hard surfaces.
 
"We've seen increased interest in our products for hard surfaces other than hardwood, particularly with our retailer audience," said Chad Nordhagen, director of marketing, Bona US. "The new Bona Stone, Tile and Laminate Wet Cleaning Pads are a perfect complement to any home for quick and easy cleaning."
 
The pads can clean a 15-in. extra-wide section of floor with every stroke and the disposable pad is larger than most cleaning pads currently available on the market, the company said. Consumers can purchase the product exclusively at Bed, Bath & Beyond and at MyBonaHome.com for $9.99.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

New Zim’s Advanced Vapor Rub available in two formats

BY Antoinette Alexander

NORTH LIMA, Ohio — Perfecta Products is further expanding its portfolio with the new Zim's Advanced Vapor Rub, available in both a traditional jar and a tube with no-mess applicator.
 
"When you talk to consumers, their number one complaint about vapor rubs is that they can be messy. We take the mess out of the vapor rub with our new easy to apply applicator,” stated Mark Smith, Perfecta Products' director of marketing and sales.
 
Zim's Advanced Vapor Rub is 100% natural and contains natural menthol, arnica extract, aloe vera, camphor, coconut oil, white beeswax and eucalyptus globulus. The product will begin appearing on shelves of independent and regional drug stores by the end of the year.

The vapor rub is the second major healthcare product Zim's has rolled out in the past two months. Earlier this year, Zim's unveiled a new Zim's Cold Sore kit to help treat and address the symptoms of cold sores.
 
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

GPhA president releases statement on the Hatch Waxman Act’s 30th anniversary

BY DSN STAFF

WASHINGTON — In honor of the 30th anniversary of the Drug Price Competition and Patent Term Restoration Act — more commonly known as the Hatch Waxman Act — which enabled manufacturers to bring generic versions of pharmaceuticals to market more easily, GPHA president Ralph Neas issued the following the statement:
 
“When President Ronald Reagan signed the Drug Price Competition and Patent Term Restoration Act 30 years ago today, few could imagine how the law would transform the healthcare landscape. Today, we know that this landmark ‘Hatch-Waxman’ legislation is responsible for improving the lives of millions of Americans by creating a new framework allowing safe, affordable generic drugs to come to the market.
 
It is instructive to look back to 1984 and note that when forecasting the law’s success, even its most enthusiastic supporters’ predictions proved wholly inadequate. Even adjusting for inflation, it is clear that the law has outpaced the greatest expectations of its champions. At the time, proponents of the law stated that, if passed, it could save Americans $1 billion. Clearly, time has proved them wrong: That prediction falls dramatically short of the savings from generic drugs in 2013 alone. This year’s Generic Drug Savings in the United States report, compiled by IMS Institute for Healthcare Informatics on behalf of GPhA, showed that generics saved $239 billion in 2013. At a time when health costs in America are threatening the sustainability of the nation’s budget, the study found that generic drugs have saved $1.46 trillion dollars over the past 10 years, contributing to the recent CBO decrease of health cost projections for the coming years.
 
It is important to remember, however, that savings are only part of the remarkable track record of achievement of the Hatch-Waxman law. In fact, the law set out to accomplish two goals: to encourage innovation of new therapies and to generate competition from lower-cost generic medicines to drive down costs. To do so, it created consistent and rigorous standards for generic manufacturers to prove their products are equivalent to brand drugs.  At the same time, it extended patent protections for brand companies. Thirty years later, by any measure, the law has been an astounding success on both fronts.
 
Generic medicines make up 86% of the drugs dispensed in 2013, up from only 18% in the pre-Hatch-Waxman era. At the same time, the brand industry has flourished, with more new drug breakthroughs over the last 30 years than ever before.
 
The Hatch-Waxman Act demonstrates that good policy that embraces compromise can benefit all Americans. Brand drug makers have profited from a reasonable extension of patent protections, and generic manufacturers have benefited as well, growing into a thriving industry that has produced approximately 12,000 safe, more affordable versions of brand drugs.  The real beneficiaries, however, are patients and taxpayers. Americans now enjoy access to more breakthrough drugs than ever, while saving hundreds of billions of dollars every year. The Hatch-Waxman Act is more than the cornerstone of the modern generic pharmaceutical industry; it is nothing short of a remarkable bipartisan legislative triumph.
 
Today, the generic industry’s future could not be brighter. The Hatch-Waxman law created a strong foundation for a dynamic and evolving generic drug industry, and with emerging opportunities from a global marketplace, expanded health coverage access, and the needs of an aging population, the industry has never been stronger. As we look forward to the next frontier of affordable medicines, biosimilars, a recent study by Express Scripts estimates that hundreds of billions of dollars in savings are at stake.  Over 10 years, the report showed, the United States would save $250 billion if just the 11 likeliest biosimilars would enter the market.
 
We must embrace the spirit of the Hatch-Waxman law and build on its remarkable achievements. It is essential to recognize that balancing competition with access to affordable medicines can revolutionize the market, offer consumers quality and safe choices, and inspire innovation. ”
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?